... so fewer patients than the current BIT225 trial, with some patients not remaining in the trial and of those who did remain in only half showed reduction of HIV (with at least 1 only being a 2% reduction) and others showing up to a 36% increase! And that company has a higher MC than BIT? I haven’t looked at their history in detail or other product development pathway - although looks like they are also testing ABX464 for effect as an anti-inflammatory for irritable bowel syndrome (http://www.abivax.com/en/news-event...x464-005-phase-2a-study-in-hiv-infection.html) but what am I missing here ... why the higher MC than BIT? Is it “just” awaiting completion and release of analysis data for the BIT225 trial?
As always this is just the gathering of my own opinion, not any form of advice and you ought to always do your own research. Thanks 8horse for bring that bit to attention.
BIT Price at posting:
8.1¢ Sentiment: Buy Disclosure: Held
